Bauvois Brigitte, Mothu Nadya, Nguyen Juliette, Nguyen-Khoa Thao, Nöel Laure-Hélène, Jungers Paul
INSERM 507, CNRS UMR 7131, Hôpital Necker, Paris, France.
Nephrol Dial Transplant. 2007 Apr;22(4):1115-22. doi: 10.1093/ndt/gfl743. Epub 2007 Jan 5.
Dysregulated renal expression of matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMP) and TGF-beta1 contribute to the development of tubulo-interstitial fibrosis characteristic of progressive forms of primary glomerulonephritis (GN). There is little information on the circulating levels of these proteins in human GNs. Here, we assessed whether different histopathological GN types could be associated with distinct plasma patterns of MMPs and regulatory proteins.
Protein levels of MMP-2, MMP-9, TGF-beta1 and TIMP-1 were measured by ELISA in plasma from venous blood of 108 untreated patients with various types of primary GN defined by kidney biopsy, namely IgAN (n=63), membranous GN (MN, n=26), minimal change nephrotic syndrome (MCNS, n=12) and focal and segmental glomerular sclerosis (FSGS, n=7), and were compared with levels in 50 healthy subjects. Plasma samples were assayed for gelatinolytic activity (zymography).
Zymography detected the proforms of MMP-2 and MMP-9. Compared with controls, IgAN patients exhibited a significant, parallel decrease in plasma levels of MMP-2, MMP-9 and TGF-beta1. In MN patients, decreased MMP-9 level contrasted with a high MMP-2 level and a normal TGF-beta1 level. In the MCNS/FSGS group, increased MMP-2 level contrasted with unchanged MMP-9 and decreased TGF-beta1 levels. Plasma concentration of TIMP-1 was elevated in all GN groups. There was no correlation between baseline MMP-2/MMP-9/TIMP-1/TGF-beta1 levels and the degree of renal dysfunction or with progression toward ESRD.
Plasma concentrations of MMP-2, MMP-9 and TGF-beta1 significantly differed between the various histopathological types of primary GNs, thus suggesting the involvement of different underlying mechanisms in the regulation of glomerular and tubulointerstitial fibrosis in these renal diseases.
基质金属蛋白酶(MMPs)、MMPs组织抑制剂(TIMPs)及转化生长因子-β1(TGF-β1)在肾脏中的表达失调,促进了原发性肾小球肾炎(GN)进展型特征性的肾小管间质纤维化的发展。关于这些蛋白在人类GN中的循环水平的信息较少。在此,我们评估了不同组织病理学类型的GN是否与MMPs及调节蛋白的不同血浆模式相关。
通过酶联免疫吸附测定法(ELISA)测量了108例经肾活检确诊的未经治疗的各种原发性GN患者静脉血血浆中MMP-2、MMP-9、TGF-β1和TIMP-1的蛋白水平,这些患者包括IgA肾病(n = 63)、膜性肾病(MN,n = 26)、微小病变肾病综合征(MCNS,n = 12)和局灶节段性肾小球硬化(FSGS,n = 7),并与50名健康受试者的水平进行比较。对血浆样本进行明胶酶解活性检测(酶谱法)。
酶谱法检测到了MMP-2和MMP-9的前体形式。与对照组相比,IgA肾病患者血浆中MMP-2、MMP-9和TGF-β1水平显著且平行下降。在MN患者中,MMP-9水平降低与MMP-2水平升高及TGF-β1水平正常形成对比。在MCNS/FSGS组中,MMP-2水平升高与MMP-9水平不变及TGF-β1水平降低形成对比。所有GN组中TIMP-1的血浆浓度均升高。基线MMP-2/MMP-9/TIMP-1/TGF-β1水平与肾功能不全程度或向终末期肾病进展之间无相关性。
不同组织病理学类型的原发性GN之间,MMP-2、MMP-9和TGF-β1的血浆浓度存在显著差异,这表明在这些肾脏疾病中,肾小球和肾小管间质纤维化的调节涉及不同的潜在机制。